Literature DB >> 17363040

Cytokine production by hepatic anaplastic large-cell lymphoma presenting as a rheumatic syndrome.

Stefan Siebert1, Nicholas Amos, Bryan D Williams, Thomas M Lawson.   

Abstract

OBJECTIVES: A variety of malignancies can present as rheumatic syndromes. Our aim was to describe a case of primary hepatic anaplastic large-cell lymphoma (ALCL) presenting as a rheumatic syndrome. We also describe cytokine production by the tumor.
METHODS: A patient with ALCL presenting with arthralgia and systemic inflammation is described. Cytokine production by the resected tumor and adjacent normal liver was assayed by enzyme-linked immunosorbent assay following in vitro culture. Medline database search of the English literature between 1976 and August 2006 was performed.
RESULTS: A 44-year-old man was admitted with generalized arthralgias, fatigue, weight loss, and night sweats. Despite a high clinical suspicion of underlying malignancy, repeated radiologically guided biopsies of bone and liver abnormalities failed to demonstrate any malignant cells. The patient improved dramatically on empirical corticosteroids but symptoms recurred on attempting to reduce the steroid dosage. He ultimately underwent partial hepatectomy for an enlarging liver lesion, which was demonstrated to be primary hepatic ALCL on immunohistochemistry. There are a few reports of ALCL presenting as bone lesions, but to our knowledge this is the first report of hepatic ALCL presenting with a rheumatic syndrome. The clinical and biochemical inflammation resolved following resection of the tumor but returned on tumor recurrence. The tumor produced large quantities of the proinflammatory cytokines interleukin-6 (IL-6) and IL-8 but did not produce tumor necrosis factor-alpha (TNF-alpha), IL-1, or IL-4.
CONCLUSIONS: Repeat biopsies may be required to diagnose underlying tumor. The ALCL tissue in our patient produced large quantities of the IL-6, which we believe was associated with the patient's systemic inflammation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17363040     DOI: 10.1016/j.semarthrit.2006.12.007

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  5 in total

1.  Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies.

Authors:  Kai Lehmberg; Kim E Nichols; Jan-Inge Henter; Michael Girschikofsky; Tatiana Greenwood; Michael Jordan; Ashish Kumar; Milen Minkov; Paul La Rosée; Sheila Weitzman
Journal:  Haematologica       Date:  2015-08       Impact factor: 9.941

2.  A multicenter study of patients with multisystem Langerhans cell histiocytosis who develop secondary hemophagocytic lymphohistiocytosis.

Authors:  Deepak Chellapandian; Melissa R Hines; Rui Zhang; Michael Jeng; Cor van den Bos; Vicente Santa-María López; Kai Lehmberg; Elena Sieni; Yini Wang; Taizo Nakano; James A Williams; Nicholas J Fustino; Itziar Astigarraga; Ira J Dunkel; Oussama Abla; Astrid G S van Halteren; Deqing Pei; Cheng Cheng; Sheila Weitzman; Lillian Sung; Kim E Nichols
Journal:  Cancer       Date:  2018-12-06       Impact factor: 6.860

3.  EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma.

Authors:  Janine Schmidt; Irina Bonzheim; Julia Steinhilber; Ivonne A Montes-Mojarro; Carlos Ortiz-Hidalgo; Wolfram Klapper; Falko Fend; Leticia Quintanilla-Martínez
Journal:  Lab Invest       Date:  2017-06-05       Impact factor: 5.662

4.  Primary pulmonary Hodgkin's lymphoma mimicking rheumatoid arthritis-associated organizing pneumonia: A case report.

Authors:  Kunyan Sun; Qing Yu; Jiaxin Zhou; Hong Zhang; Li Gao; Lin Nong; Mangju Wang; Chengli Que
Journal:  Thorac Cancer       Date:  2021-04-03       Impact factor: 3.500

5.  High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides.

Authors:  Marshall E Kadin; Igor Y Pavlov; Julio C Delgado; Eric C Vonderheid
Journal:  J Invest Dermatol       Date:  2011-11-10       Impact factor: 8.551

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.